Popular Stories
Avise Analytics | FDA
515
archive,tag,tag-fda,tag-515,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-7.4,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

FDA Tag

  • All
  • Biotechnology
  • Cannabis
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
A Potential Disruptor In The Micro-Endoscopic Device Market

Medigus Ltd, (NASDAQ:MDGS) a pioneer in developing cutting-edge minimally invasive surgical tools and imaging solutions for medical as well as industrial use, announced that the company, along with A.M surgical has landed a “Substantial Commercial Order” for manufacturing 1,400 units of its integrated visualization device...

Initiates Make-or-Break Phase 3 Clinical Trials in AngelMan Syndrome

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company developing novel therapeutics for rare neurological disorders, announced the launch of a crucial phase 3 clinical trial in Angelman Syndrome named NEPTUNE. OV101, its lead candidate for  the treatment of syndrome and Fragile X Syndrome is a delta-selective...

Gene Therapy offers Cure for Bubble Boy Syndrome

Severe combined immunodeficiency (SCID) or “Bubble Boy Syndrome” is a rare genetic disorder caused by gene mutations that inhibit the functioning of immune cells. Children afflicted with this condition are healthy in appearance but are susceptible to severe infections, even a common cold can prove...

ReWalk Raises $5M for its ReStore Exosuit for Stroke Victims

Standing Tall ReWalk Robotics (NASDAQ: RWLK) recently received an approval for its ReStore exoskeleton system, indicated for rehabilitation of stroke victims, from the FDA. The company also manufactures ReWalk robotic exoskeleton, the first to receive FDA approval for personal and rehabilitation use in the United States. It...

Can Cara Therapeutics buck the trend?

Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic and diluted share compared to a net loss of $16.8 million, or $0.51 per basic and diluted share, for the first...

WordPress Video Lightbox Plugin